Prospective investors should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See "Cautionary Note Regarding Forward-Looking Statements." You should review the "Risk Factors" section of this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Company History and Our Business

AgriFORCE Growing Systems Ltd. was incorporated as a private company by Articles of Incorporation issued pursuant to the provisions of the British Columbia Business Corporations Act on December 22, 2017. The Company's registered and records office address is at 300 - 2233 Columbia Street, Vancouver, British Columbia, Canada, V5Y 0M6. On February 13, 2018, the Company changed its name from 1146470 B.C. Ltd to Canivate Growing Systems Ltd. On November 22, 2019, the Company changed its name from Canivate Growing Systems Ltd. to AgriFORCE Growing Systems Ltd.

The Company is an innovative agriculture-focused technology company that delivers reliable, financially robust solutions for high value crops through our proprietary facility design and automation intellectual property to businesses and enterprises globally. The Company intends to operate in the plant based pharmaceutical, nutraceutical, and other high value crop markets using its unique proprietary facility design and hydroponics based automated growing system that enable cultivators to effectively grow crops in a controlled environment. The Company calls its facility design and automated growing system the "AgriFORCE grow house". The Company has designed its AgriFORCE grow house to produce in virtually any environmental condition and to optimize crop yields to as near their full genetic potential as possible whilst substantially eliminating the need for the use of pesticides and/or irradiation.

Status as an Emerging Growth Company

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for private companies.





16






We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an "emerging growth company," we intend to rely on certain of these exemptions from, without limitation, (i) providing an auditor's attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (PCAOB) regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an "emerging growth company" until the earliest of (a) the last day of our fiscal year following the fifth anniversary of the closing of this offering, (b) the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion, (c) the last day of our fiscal year in which we are deemed to be a "large accelerated filer" as defined in Rule 12b-2 under the Securities Exchange Act of 1934, or Exchange Act (which would occur if the market value of our equity securities that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter), or (d) the date on which we have issued more than $1 billion in nonconvertible debt during the preceding three-year period.





Our Business Plan


The Company plans to develop its business by focusing on both an organic growth plan and through M&A. The Company's organic growth plan is focused on four distinct phases:





AgriFORCE Solutions



PHASE 1: COMPLETED: 2017-2021



    ?   Conceptualization, engineering, and design of facility and systems.
    ?   Completed selection process of key environmental systems with preferred
        vendors.
    ?   The signing of revenue contracts with the Exclusive Independent Operator
        (EIO) for the first three facilities completed.
    ?   The arrangement of three offtake agreements signed with Exclusive
        Independent Operator (EIO) for those three facilities when complete.
        (Subsequently these agreements were terminated in Q2 2021)
    ?   Selection and Land Purchase agreement in Coachella, CA for 41.37-acre
        parcel subject to financing.
    ?   ForceFilm material ordered.




PHASE 2: 2022-2023:



    ?   Complete the financing for, and purchase of, the 41.37-acre parcel in
        Coachella, CA
    ?   Complete new contracts' structures for those first three facilities with
        new independent operators.
    ?   Site preparation and utilities infrastructure build out for the campus (up
        to eight facilities).
    ?   Fit out and complete genetics lab for micropropagation, breeding, and R&D
        to achieve near term revenue (8 months) of the sale of tissue culture
        clones for variant crops.
    ?   Additional raw materials procurement of AgriFORCE IP specific automated
        grow system, supplemental grow lighting and controls systems, and
        manufacture of the building envelope materials.
    ?   Conceptualization and design of CEA solution grow house
    ?   Focus on the delivery and installation of the first facility.
    ?   Initiate the design of a R&D facility for food solutions and plant-based
        pharma.




17







PHASE 3: 2023-2025:



    ?   Focus on the delivery and installation of the second and third facilities.
        Proof of quantitative and qualitative benefits will drive both sales
        pipeline acceleration for subsequent years.
    ?   Complete the design and construction of a R&D facility for food solutions
        and plant-based pharma. Commence engagement with universities and
        pharmaceutical companies.
    ?   Construct advanced CEA solution for food and high value crops and operate
        successfully.
    ?   Finalize the design and engineering of advanced large-scale CEA solution
        for food and high value crops with construction commencement late in the
        third year. Commence engagement with local restaurants and grocery stores
        and develop food solution branding strategies.




PHASE 4: 2026:



    ?   Focus on delivery and installation of additional facilities.
    ?   Expand geographic presence into other states whilst also introducing the
        grow house to other international markets with a view to securing
        additional locations and markets by year four.
    ?   Targeted additional contracts of three facilities.
    ?   Commence and complete first advanced nutraceutical and plant-based pharma
        CEA commercial facility by end of year 4.



The Company's initial AgriFORCE grow houses are planned to be constructed in California.





AgriFORCE Brands



PHASE 1: COMPLETED: 2017-2020



    ?   Product and Process Testing and Validation (Completed)
    ?   Filing of US and International Patent (Completed)
    ?   Conceptual Engineering and Preliminary Budgeting on Commercial Pilot Plant
        (Completed)




PHASE 2: 2021-2022



    ?   Design, Build, Start-up and Operation of the Pilot Plant
    ?   Develop Range of Finished Products in Grain Flours, Protein Flours,
        Cereals and Juices
    ?   Collaborate with Nutritional Flour Medical Research Institute (an IRS
        section 501(c)(3) Medical Research Organization) funded by private &
        public research grants




PHASE 3: 2022-2023



    ?   Launch First Range of Products in US/Canada
    ?   Drive Business with Finished Products in direct to consumer ("D2C"),
        Retail, Food Service
    ?   Drive Business as Ingredients for Bakery, Snack and Plant Based Protein
        Products Manufacturers
    ?   Develop Manufacturing Base through Partnerships and Licensing
    ?   Conceptual Engineering and Preliminary Budgeting on Large-Scale Processing
        Plant




PHASE 4: 2024-2025



    ?   Expand Product Range in US/Canada
    ?   Expand Business to other Geographies (select Markets in Europe, Asia,
        Latin America)
    ?   Design, Build Start-up and Operation of Large-Scale Processing Plan



Merger and Acquisition ("M&A")

With respect to M&A growth, the Company is creating a separate corporate office to aggressively pursue acquisitions. The Company will focus on identifying target companies in the key four pillars of its platform where each separate element of the business has its existing legacy business and can leverage across areas of expertise to expand their business footprint. The Company believes that a buy and build strategy will provide unique opportunities for innovation across each segment of the Ag-Tech market we serve. Our unique IP combined with the know-how and IP of acquired companies will create additional value if the way we grow or produce crops. The Company believes there is currently no other public traded publicly in the United States pursing this model.

COVID-19 or any pandemic, epidemic or outbreak of an infectious disease in the United States or elsewhere may adversely affect our business.

The COVID-19 virus has had unpredictable and unprecedented impacts in the United States and around the world. The World Health Organization has declared the outbreak of COVID-19 as a "pandemic," or a worldwide spread of a new disease. Many countries around the world have imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus. In the United States, federal, state and local governments have enacted restrictions on travel, gatherings, and workplaces, with exceptions made for essential workers and businesses. As of the date of this filing, we have not been declared an essential business. As a result, we may be required to substantially reduce or cease operations in response to governmental action or decree as a result of COVID-19. We are still assessing the effect on our business from COVID-19 and any actions implemented by the federal, state and local governments. We have implemented safety protocols to protect our staff, but we cannot offer any assurance that COVID-19 or any other pandemic, epidemic or outbreak of an infectious disease in the United States or elsewhere, will not materially and adversely affect our business.





18






FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021





Results of Operations


The following discussion should be read in conjunction with the condensed unaudited financial statements for the interim periods ended March 31, 2022 and 2021 respectively, included in this report.





Revenues


The Company has generated no revenue since inception.





Operating Expenses


Operating expenses increased in the three months ended March 31, 2022 as compared to March 31, 2021 by $1,868,997 or 210%, primarily due to an increase in wages and salaries by $618,976, increase in research and development by $366,544, increase in investor relations expenses of $268,652 and increase in office and administrative expenses by $252,751, as the Company entered into growth phase post IPO and increased its staff and operations.





Other (Income) / Expenses


Other expenses for the three months ended March 31, 2022 mainly relate to the change in fair value of warrant liability amounting to $457,042 and foreign exchange losses of $64,508.





Net Loss


The Company recorded a net loss of $3,281,286 for the three months ended March 31, 2022 as compared to a net loss of $884,606 for the three months ended March 31, 2021. The increase in net loss is due to the total increase in operating expenses and other expenses outlined above.

Liquidity and Capital Resources

The Company's primary need for liquidity is to fund working capital requirements, capital expenditures, and for general corporate purposes. The Company's ability to fund operations and make planned capital expenditures and debt service obligations depends on future operating performance and cash flows, which are subject to prevailing economic conditions, financial markets, business and other factors. We have recorded a net loss of $3,281,286 for the three months ended March 31, 2022, and a net loss of $884,606 for the three months ended March 31, 2021. We have recorded an accumulated deficit of $23,182,278 as of March 31, 2022 and $19,900,992 as of December 31, 2021. Net cash used in operating activities for the three months ended March 31, 2022 and March 31, 2021 was $2,870,654 and $371,978, respectively.

We had $4,378,121 in cash as at March 31, 2022 as compared to $7,775,290 as at December 31, 2021.

Our future capital requirements will depend on many factors, including:





?   the cost and timing of our regulatory activities, especially the process to
    obtain regulatory approval for our intellectual properties in the U.S. and in
    foreign countries
?   the costs of R&D activities we undertake to further develop our technology
?   the costs of constructing our grow houses, including any impact of
    complications, delays, and other unknown events
?   the costs of commercialization activities, including sales, marketing and
    production
?   the level of working capital required to support our growth
?   our need for additional personnel, information technology or other operating
    infrastructure to support our growth and operations as a public company



The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company is at the stage of development of its first facility and other IP. As such it is likely that additional financing will be needed by the Company to fund its operations and to develop and commercialize its technology. These factors raise substantial doubt about the Company's ability to continue as a going concern.

For the next twelve months from issuance of these financial statements, the Company will seek to obtain additional capital through the sale of debt or equity financings or other arrangements to fund operations; however, there can be no assurance that the Company will be able to raise needed capital under acceptable terms, if at all. The sale of additional equity may dilute existing shareholders and newly issued shares may contain senior rights and preferences compared to currently outstanding common shares. Issued debt securities may contain covenants and limit the Company's ability to pay dividends or make other distributions to shareholders. If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued. Due to the uncertainty in the Company's ability to raise capital, management believes that there is substantial doubt in the Company's ability to continue as a going concern for twelve months from the issuance of these financial statements.





19







Cash Flows


The net cash used by operating activities for the three months ended March 31, 2022 is attributable to a net loss of $3,281,286 due to operating costs associated with wages, investor relations, consulting expenses, research and development, and general administrative expenses. The net loss was adjusted primarily by non-cash expenses related to change in fair value of warrants of $457,042, shared based compensation of $157,982, shares issued for consulting services of $88,071, and shares issued for compensation of $97,121. For the three months ending March 31, 2021 net cash used by operating activities was attributable to net loss of $884,606 owing to wages, consulting expenses, professional fees, research and development expenses and general administrative expenses. The net loss was adjusted primarily by non-cash expenses shares issued for consulting services amounting to $188,327 and shared based compensation of $90,242.

The net cash used in investing activities for three months ended March 31, 2022 related to the payment against acquisition of intangible asset.

There was no cash provided by financing activities for the three months ended March 31, 2022. Whereas, cash flow from financing activities for the three months ended March 31, 2021 represents proceeds from issuance of senior secured debentures of $600,000 and related financing costs of $69,000.





Recent Financings


On March 24, 2021, the Company entered into a securities purchase agreement with certain accredited investors for the purchase of $750,000 in principal amount ($600,000 subscription amount) of senior secured debentures originally due June 24, 2021. The debentures were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, to certain purchasers who are accredited investors within the meaning of Rule 501 under the Securities Act of 1933, as amended. On June 24, 2021, the due date was extended, and the senior secured debentures were repaid in full on July 13, 2021.

On July 12, 2021, the Company completed its IPO whereby it sold a total of 3,127,998 units, each consisting of one common share and one Series A warrant to purchase one common share, at a public offering price of $5.00 for gross proceeds of $15,639,990. The Company received net proceeds from the IPO of $14,388,791, after deducting underwriting discounts and commissions of 1,251,199.

Off Balance Sheet Arrangements





None.


Significant Accounting Policies

See the footnotes to our unaudited financial statements for the three months ended March 31, 2022 and 2021, included with this quarterly report.

© Edgar Online, source Glimpses